A phase 1, open-label, dose-escalation study to evaluate the safety, pharmacokinetcs, and pharmacodynamics of oral azacitidine in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML) - Garcia-Manero, G (Blood, 2009)
et al.